4//SEC Filing
Kearney Terrence C 4
Accession 0001179110-20-010439
CIK 0001280600other
Filed
Oct 12, 8:00 PM ET
Accepted
Oct 13, 7:14 PM ET
Size
25.1 KB
Accession
0001179110-20-010439
Insider Transaction Report
Form 4
Kearney Terrence C
Director
Transactions
- Exercise/Conversion
Option to Purchase Common Stock
2020-10-12−10,000→ 0 totalExercise: $27.97Exp: 2026-03-03→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2020-10-12$30.17/sh+7,500$226,275→ 42,627 total - Exercise/Conversion
Option to Purchase Common Stock
2020-10-12−20,000→ 0 totalExercise: $28.37Exp: 2024-07-14→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2020-10-12$28.37/sh+20,000$567,400→ 25,127 total - Sale
Common Stock
2020-10-12$117.82/sh−2,200$259,204→ 40,427 total - Sale
Common Stock
2020-10-12$119.78/sh−16,210$1,941,634→ 6,040 total - Exercise/Conversion
Option to Purchase Common Stock
2020-10-12−7,500→ 0 totalExercise: $30.17Exp: 2027-03-02→ Common Stock (7,500 underlying) - Sale
Common Stock
2020-10-12$119.11/sh−18,177$2,165,062→ 22,250 total - Exercise/Conversion
Common Stock
2020-10-12$27.97/sh+10,000$279,700→ 35,127 total - Sale
Common Stock
2020-10-12$120.57/sh−913$110,080→ 5,127 total
Footnotes (7)
- [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.29 to $118.08 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.50 to $119.49 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.50 to $120.48 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.50 to $120.70 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
- [F6]The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant date.
- [F7]The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date.
Documents
Issuer
ACCELERON PHARMA INC
CIK 0001280600
Entity typeother
Related Parties
1- filerCIK 0001289098
Filing Metadata
- Form type
- 4
- Filed
- Oct 12, 8:00 PM ET
- Accepted
- Oct 13, 7:14 PM ET
- Size
- 25.1 KB